Sugi Predict

Sugi Predict / Targets / LIG3

LIG3

DNA ligase 3 · P49916 · LIG3 on Sugi Atlas →

104 patent compounds predicted against LIG3, 78 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13401789 SCHEMBL13401789 1.00 1/20
SCHEMBL19298155 SCHEMBL19298155 1.00 1/20
SCHEMBL19334306 SCHEMBL19334306 0.83 1/20
SCHEMBL14959162 SCHEMBL14959162 0.78 1/20
SCHEMBL13401821 SCHEMBL13401821 0.75 1/20
SCHEMBL17927035 SCHEMBL17927035 0.71 1/20
SCHEMBL17927036 SCHEMBL17927036 0.71 1/20
SCHEMBL29374901 SCHEMBL29374901 0.71 1/20
SCHEMBL22506412 SCHEMBL22506412 0.69 1/20
SCHEMBL22506486 SCHEMBL22506486 0.63 1/20
SCHEMBL19334492 SCHEMBL19334492 0.62 1/20
SCHEMBL17080648 SCHEMBL17080648 0.61 1/20
SCHEMBL13401495 SCHEMBL13401495 0.58 1/20
SCHEMBL13401793 SCHEMBL13401793 0.58 1/20
SCHEMBL13745514 SCHEMBL13745514 0.58 1/20
SCHEMBL13402123 SCHEMBL13402123 0.56 1/20
SCHEMBL13401791 SCHEMBL13401791 0.56 1/20
SCHEMBL3666434 SCHEMBL3666434 0.56 1/20
SCHEMBL4407466 SCHEMBL4407466 0.55 1/20
SCHEMBL7436514 SCHEMBL7436514 0.55 1/20

Clinical trials — most relevant to LIG3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency PHASE2/PHASE3RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) PHASE2COMPLETED
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Chromosomal Translocations in Chandigarh Police nanCOMPLETED
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis nanCOMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome nanUNKNOWN
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
DNA Repair in Patients With Stable Angina. nanUNKNOWN
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews nanCOMPLETED
Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer nanRECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LIG3 binder may also engage these)

ProteinNameSimilarity
P97386 — 1.000 P97386 →
P27008 — 0.987 P27008 →
POLQ DNA polymerase theta 0.985 landscape →
Q8N1G2 — 0.985 Q8N1G2 →
E1BYJ2 — 0.984 E1BYJ2 →
Q9DBC3 — 0.983 Q9DBC3 →
Q7ZU90 — 0.983 Q7ZU90 →
Q95K79 — 0.983 Q95K79 →
Q5R981 — 0.983 Q5R981 →
Q96BT7 — 0.983 Q96BT7 →
Q64398 — 0.983 Q64398 →
Q9UJA3 — 0.982 Q9UJA3 →
Q15326 — 0.981 Q15326 →
Q4KWH5 — 0.981 Q4KWH5 →
Q1DKE7 — 0.981 Q1DKE7 →
P23881 — 0.981 P23881 →
Q9LL84 — 0.981 Q9LL84 →
Q7X7E9 — 0.981 Q7X7E9 →
A9LLI8 — 0.981 A9LLI8 →
O00423 — 0.981 O00423 →
KAT2A Histone acetyltransferase KAT2A 0.981 landscape →
Q91821 — 0.981 Q91821 →
O35385 — 0.980 O35385 →
MSH6 DNA mismatch repair protein Msh6 0.980 landscape →
P31669 — 0.980 P31669 →
O14830 — 0.980 O14830 →
LIG4 DNA ligase 4 0.980 landscape →
Q8K4M9 — 0.980 Q8K4M9 →
Q9M041 — 0.980 Q9M041 →
Q812E4 — 0.980 Q812E4 →